Sanofi has announced the appointment of Brian Foard as the new head of specialty care, effective March 1. This leadership change comes as the company prepares for a transition under the new CEO, Belén Garijo, signaling a strategic shift in its approach to specialty pharmaceuticals.
The appointment of Foard, who brings extensive experience in the specialty sector, underscores Sanofi’s commitment to enhancing its portfolio in this critical area. As the demand for specialized treatments continues to rise, Sanofi aims to strengthen its position in the market, particularly in therapeutic areas where precision medicine is becoming increasingly important.
Meanwhile, Biogen’s chair is set to retire in June, marking the end of an era for the company. This leadership change could have significant implications for Biogen’s strategic direction and its ongoing efforts to innovate in the neurology space. The concurrent transitions in both companies highlight a period of evolution in the pharmaceutical landscape, as firms adapt to new challenges and opportunities.
Start your 7-day trial and see what the database can do →
